Plant Name: Copaifera paupera
Taxonomic Information:
Plant ID: NPO18847
Plant Latin Name: Copaifera paupera
Taxonomy Genus: Copaifera
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
64942-2
Used in Medicines:
Unknown.
Geographical Distribution:
Brazil; Bolivia; Peru
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NR0B1; | |
| NR3C1; | |
| HIF1A; | |
| SLC6A2; SLC6A3; SLCO1B3; SLCO1B1; | |
| PAX8; RAB9A; NPC1; LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 0 group B | NR0B1 | Nuclear receptor subfamily 0 group B member 1 | P51843 | CHEMBL1795094 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| SLC superfamily of solute carriers | SLC6A3 | Dopamine transporter | Q01959 | CHEMBL238 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | PAX8 | Paired box protein Pax-8 | Q06710 | CHEMBL2362980 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.312E-09 | 2.028E-04 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.021E-07 | 5.559E-04 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.278E-06 | 5.567E-03 | CYP2C19, CYP2C9, CYP3A4, NPC1, NR0B1 |
| MF | GO:0005215; transporter activity | GO:0005330; dopamine:sodium symporter activity | 1.929E-06 | 6.168E-03 | SLC6A2, SLC6A3 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 2.747E-06 | 7.477E-03 | CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.856E-06 | 8.396E-03 | CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.478E-06 | 1.282E-02 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0023052; signaling | GO:0051583; dopamine uptake involved in synaptic transmission | 9.631E-06 | 1.311E-02 | SLC6A2, SLC6A3 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.884E-05 | 2.990E-02 | CYP2C19, CYP2C9 |
| MF | GO:0005215; transporter activity | GO:0015291; secondary active transmembrane transporter activity | 3.886E-05 | 3.539E-02 | SLC6A2, SLC6A3, SLCO1B1, SLCO1B3 |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 4.225E-05 | 3.539E-02 | SMN1, SMN2 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 4.991E-05 | 3.748E-02 | SMN1, SMN2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.516E-06 | 5.304E-05 | CYP2C9, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.131E-05 | 2.710E-04 | CYP2C9, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.323E-05 | 2.710E-04 | SLCO1B1, SLCO1B3, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.579E-05 | 3.132E-04 | CYP2C9, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.103E-03 | 7.070E-03 | CYP2C9, CYP2C19 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.212E-03 | 7.070E-03 | CYP2C9, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.526E-03 | 7.628E-03 | CYP2C9, CYP3A4 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.543E-03 | 1.550E-02 | CYP2C9, CYP2C19 |
| 09120 Genetic Information Processing | 09122 Translation | hsa03013 | RNA transport | 8.152E-03 | 3.170E-02 | SMN2, SMN1 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 2.296E-02 | 8.035E-02 | PAX8 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | NR3C1; |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | NR3C1; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; NR3C1; |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NR3C1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; NR3C1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | NR3C1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | NR3C1; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | NR3C1; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; |
| NA: NA | Non-infectious rhinitis | NA | NR3C1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | NR3C1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
